Life science contract organisations balance real estate ownership (73 per cent) vs leasing (27 per cent) based on financial, operational, and strategic considerations.
Pharmaceutical giants are transforming their real estate strategies. Industry leaders are shifting from traditional property ownership to strategic lease-ownership balancing for financial efficiency and flexibility.